XML 37 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Segment Information
 9 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 12. Segment Information

 

The following tables set forth our segment information:

 

  

Three Months Ended December 31,

  

Nine Months Ended December 31,

 
  

2022

  

2021

  

2022

  

2021

 

Revenues:

                

Clinical Genomics

 $15,585  $16,485  $48,525  $16,485 

Sterilization and Disinfection Control

  16,283   13,831   48,021   43,014 

Biopharmaceutical Development

  11,646   12,756   34,757   32,188 

Calibration Solutions

  10,773   11,624   32,186   33,769 

Total revenues (a)

 $54,287  $54,696  $163,489  $125,456 
                 

Gross profit

                

Clinical Genomics

 $8,045  $3,924  $26,535  $3,924 

Sterilization and Disinfection Control

  11,614   9,945   34,581   31,859 

Biopharmaceutical Development

  7,359   8,768   21,993   20,061 

Calibration Solutions

  5,740   6,090   17,411   18,330 

Reportable segment gross profit

  32,758   28,727   100,520   74,174 

Corporate and Other (b)

  7   (100)  (28)  (196)

Gross profit

 $32,765  $28,627  $100,492  $73,978 

Reconciling Items:

                

Operating expenses

  29,363   31,139   97,689   69,166 

Operating income (loss)

  3,402   (2,512)  2,803   4,812 

Nonoperating expense (income), net

  1,486   (171)  2,915   1,192 

Earnings (loss) before income taxes

 $1,916  $(2,341) $(112) $3,620 

 

 

(a)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

 

(b)

Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other. 

 

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.

 

  

December 31,

  

March 31,

 
  

2022

  

2022

 

Clinical Genomics

 $14,591  $11,802 

Sterilization and Disinfection Control

  3,022   2,176 

Biopharmaceutical Development

  7,797   4,495 

Calibration Solutions

  8,329   6,133 

Total inventories

 $33,739  $24,606